The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Open accessAbstract
Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the precision afforded by complementary binding of an ASO to its target transcript of interest, ASOs have emerged as an invaluable tool in specifically altering levels and/or processing of a variety of proteins involved in neurodegenerative diseases, most of which have been the disease-causing protein itself (38, 51–54).”
From Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration (2023) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-citationReaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-43 · Cited by 1,285
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,250
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationWild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS
Bosco, D. A., Morfini, G. A., Karabacak, M., Song, Y., Gros‐Louis, F., Pasinelli, P., Goolsby, H., Fontaine, B. A., Lemay, N., McKenna-Yasek, D. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2660 · Cited by 685
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationLagier‐Tourenne, C., Baughn, M. W., Rigo, F., Sun, S., Liu, P., Li, H., Jiang, J., Watt, A. T., Chun, S. J., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 585
Self-citationJiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536
Self-citationDeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Self-citationAntisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Is SOD1 loss of function involved in amyotrophic lateral sclerosis?
Saccon, R. A., Bunton-Stasyshyn, R. K. A., Fisher, E., & Fratta, P. (2013) · Brain · doi:10.1093/brain/awt097 · Cited by 339
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
Steinacker, P., Feneberg, E., Weishaupt, J. H., Brettschneider, J., Tumani, H., Andersen, P. M., Arnim, C. A. F. V., Böhm, S., Kassubek, J., Kubisch, C., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311387 · Cited by 316
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
Self-citationAndersen, P. M. (1997) · Brain · doi:10.1093/brain/120.10.1723 · Cited by 301
Urushitani, M., Ezzi, S. A., & Julien, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606201104 · Cited by 237
An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS
Rakhit, R., Robertson, J., Velde, C. V., Horne, P., Ruth, D. M., Griffin, J. K., Cleveland, D. W., Cashman, N. R., & Chakrabartty, A. (2007) · Nature Medicine · doi:10.1038/nm1559 · Cited by 231
Foust, K. D., Salazar, D. L., Likhite, S. B., Ferraiuolo, L., Ditsworth, D., Ilieva, H. S., Meyer, K., Schmelzer, L., Braun, L., Cleveland, D. W., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.211 · Cited by 211
Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism
Ferraiuolo, L., Meyer, K., Sherwood, T. W., Vick, J. S., Likhite, S. B., Frakes, A., Miranda, C. J., Braun, L., Heath, P. R., Pineda, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607496113 · Cited by 205
Gros‐Louis, F., Soucy, G., Larivière, R., & Julien, J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06683.x · Cited by 189
Ratovitski, T., Corson, L., Strain, J., Wong, P., Cleveland, D. W., Culotta, V., & Borchelt, D. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1451 · Cited by 180
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model
Schoch, K. M., DeVos, S. L., Miller, R. L., Chun, S. J., Norrbom, M., Wozniak, D. F., Dawson, H. N., Bennett, C. F., Rigo, F., & Miller, T. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.042 · Cited by 175
Self-citationThomsen, G. M., Gowing, G., Latter, J., Chen, M., Vit, J., Staggenborg, K., Avalos, P., Alkaslasi, M. R., Ferraiuolo, L., Likhite, S. B., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2037-14.2014 · Cited by 137
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS
Benatar, M. G., Wuu, J., Andersen, P. M., Atassi, N., David, W., Cudkowicz, M., & Schoenfeld, D. (2018) · Neurology · doi:10.1212/wnl.0000000000004960 · Cited by 136
Self-citationSOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
Winer, L. K., Srinivasan, D., Chun, S. J., Lacomis, D., Jaffa, M., Fagan, A. M., Holtzman, D. M., Wancewicz, E. V., Bennett, C. F., Bowser, R. P., et al. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.593 · Cited by 113
Self-citationMisfolded SOD1 is not a primary component of sporadic ALS
Cruz, S. D., Bui, A., Saberi, S., Lee, S. K., Stauffer, J. E., McAlonis‐Downes, M., Schulte, D. J., Pizzo, D. P., Parone, P. A., Cleveland, D. W., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1688-8 · Cited by 113
Targeting of Monomer/Misfolded SOD1 as a Therapeutic Strategy for Amyotrophic Lateral Sclerosis
Liu, H.-N., Tjostheim, S., DaSilva, K., Taylor, D., Zhao, B., Rakhit, R., Brown, M., Chakrabartty, A., McLaurin, J., & Robertson, J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5053-11.2012 · Cited by 107
Stoica, L., Todeasa, S. H., Cabrera, G. T., Salameh, J. S., ElMallah, M. K., Mueller, C., Brown, R. H., & Sena‐Esteves, M. (2016) · Annals of Neurology · doi:10.1002/ana.24618 · Cited by 106
Defining SOD1 ALS natural history to guide therapeutic clinical trial design
Bali, T., Self, W. K., Liu, J., Siddique, T., Wang, L. H., Bird, T. D., Ratti, E., Atassi, N., Boylan, K., Glass, J. D., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313521 · Cited by 101
Self-citationBruijn, L. I., & Cleveland, D. W. (1996) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1996.tb00907.x · Cited by 99
Fischer, L. R., Li, Y., Asress, S. A., Jones, D. P., & Glass, J. D. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.020 · Cited by 98
Disease progression of human SOD1 (G93A) transgenic ALS model rats
Matsumoto, A., Okada, Y., Nakamichi, M., Nakamura, M., Toyama, Y., Sobue, G., Nagai, M., Aoki, M., Itoyama, Y., & Okano, H. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20708 · Cited by 88
MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models
Hoye, M. L., Koval, E. D., Wegener, A. J., Hyman, T. S., Yang, C., O'Brien, D. R., Miller, R. L., Cole, T., Schoch, K. M., Shen, T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3582-16.2017 · Cited by 82
Self-citationElectrophysiological analysis of a murine model of motoneuron disease
Mancuso, R., Santos-Nogueira, E., Osta, R., & Navarro, X. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.01.045 · Cited by 74
McCombe, P., Pfluger, C. M., Singh, P. K., Lim, C. Y. H., Airey, C. A., & Henderson, R. D. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.04.032 · Cited by 61
In vivo kinetic approach reveals slow SOD1 turnover in the CNS
Crisp, M. J., Mawuenyega, K. G., Patterson, B. W., Reddy, N. C., Chott, R. C., Self, W. K., Weihl, C. C., Jockel, J., Varadhachary, A. S., Bucelli, R. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80705 · Cited by 59
Self-citationLu, C., Petzold, A., Kalmár, B., Dick, J. R. T., Malaspina, A., & Greensmith, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040998 · Cited by 55
Development of a simple, rapid, and robust intrathecal catheterization method in the rat
Mazur, C., Fitzsimmons, B., Kamme, F., Nichols, B., Powers, B. E., & Wancewicz, E. V. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.02.001 · Cited by 40
Lange, D. J., Andersen, P. M., Remanan, R., Marklund, S. L., & Benjamin, D. (2012) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/17482968.2012.724074 · Cited by 38
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy
(2016) · Case Medical Research · doi:10.31525/cmr-29dc5f3 · Cited by 38
Antisense-Mediated Exon Inclusion
Hua, Y., & Krainer, A. R. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-767-5_20 · Cited by 31
Gene-Targeted Therapies for the Central Nervous System
Miller, T. M., Smith, R. A., Kordasiewicz, H. B., & Kaspar, B. K. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.nnr70007 · Cited by 24
Self-citationPresymptomatic electrophysiological tests predict clinical onset and survival in SOD1G93A ALS mice
Mancuso, R., Osta, R., & Navarro, X. (2014) · Muscle & Nerve · doi:10.1002/mus.24237 · Cited by 22
Cited by
Sorted by citations
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204705 · Cited by 966
Self-citationPhase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
Self-citationMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
ALS Genetics: Gains, Losses, and Implications for Future Therapies
Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.022 · Cited by 370
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
Self-citation
Metadata
- Authors
- McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., Schoch, K. M., Hoye, M. L., Shabsovich, M., Sun, L., Luo, Y., Zhang, M., Thankamony, S., Salzman, D. W., Cudkowicz, M., Graham, D. L., Bennett, C. F., Kordasiewicz, H. B., Swayze, E. E., & Miller, T. M.
- Affiliations
- Biogen (United States) (US)
- Ionis Pharmaceuticals (United States) (US)
- Washington University in St. Louis (US)
- Harvard University (US)
- Corresponding author
- Miller, Timothy M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-16
- Volume
- 128
- Issue
- 8
- Pages
- 3558-3567
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6063493
- OpenAlex
- W2884390718
- Cited by
- 279
- References
- 46
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 48 · 2023: 35 · 2022: 32 · 2021: 30 · 2020: 42 · 2019: 22 · 2018: 4
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Biogen
- Ionis Pharmaceuticals
- National Institutes of Health (50 and)
- National Institute of Neurological Disorders and Stroke (U01NS084970, R01NS078398)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- antisense oligonucleotides, amyotrophic lateral sclerosis, SOD1, SOD1 G93A mice, familial ALS, compound muscle action potential, neurofilament heavy chain, biomarkers, survival extension, ALS therapeutics
- MeSH terms
- Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Humans, Superoxide Dismutase, Muscle, Skeletal, Oligodeoxyribonucleotides, Antisense, Rats, Rats, Transgenic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
